Tiziana Life Sciences Receives FDA Acceptance For Fast Track Designation Submission Of Intranasal Foralumab For Treating Non-Active Secondary-Progressive Multiple Sclerosis (Na-SPMS)
Tiziana Life Sciences Receives FDA Acceptance For Fast Track Designation Submission Of Intranasal Foralumab For Treating Non-Active Secondary-Progressive Multiple Sclerosis (Na-SPMS)
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.